Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lycke, Jan
RAM-MS, NCT03477500 / 2017-001362-25: Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS	Recruiting	3	100	Europe	Cyclophosphamide and ATG, Sendoxan, Alemtuzumab, Lemtrada, Cladribine Pill, Mavenclad, Ocrelizumab, Ocrevus	Haukeland University Hospital	Multiple Sclerosis	03/24	03/26
NCT03674099: Imatinib for Multiple Sclerosis (MS) Relapses	Recruiting	2	200	Europe	Imatinib Mesylate, Methylprednisolone	Tomas Olsson, The Swedish Research Council	Multiple Sclerosis	12/22	07/23